Search Results - "Meulen, Jan H. ter"

In vitro and in vivo inhibitory effects of TLR4 agonist, glucopyranosyl lipid A (GLA), on allergic rhinitis caused by Japanese cedar pollen by Matsumoto, Koji, Kouzaki, Hideaki, Yamamoto, Sayuri, Kikuoka, Hirotaka, Tojima, Ichiro, Meulen, Jan H., Shimizu, Takeshi

Get full text

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease by Coller, Beth-Ann G, Clements, David E, Bett, Andrew J, Sagar, Sangeetha L, Ter Meulen, Jan H

“…Abstract Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many…”
Get full text

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A by Lu, Hailing, Betancur, Alec, Chen, Michael, ter Meulen, Jan H.

“…Intratumoral (IT) injections of Glucopyranosyl lipid A (G100), a synthetic toll-like receptor 4 (TLR4) agonist formulated in a stable emulsion, resulted in…”
Get full text

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 by Somaiah, Neeta, Block, Matthew S, Kim, Joseph W, Shapiro, Geoffrey I, Do, Khanh T, Hwu, Patrick, Eder, Joseph P, Jones, Robin L, Lu, Hailing, Ter Meulen, Jan H, Bohac, Chet, Chen, Michael, Hsu, Frank J, Gnjatic, Sacha, Pollack, Seth M

“…LV305 is a modified, third-generation, nonreplicating, integration-deficient lentivirus-based vector designed to selectively transduce dendritic cells . LV305…”
Get full text

First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1 by Mahipal, Amit, Ejadi, Samuel, Gnjatic, Sacha, Kim-Schulze, Seunghee, Lu, Hailing, ter Meulen, Jan H., Kenney, Richard, Odunsi, Kunle

“…Human tumor cells express antigens that serve as targets for the host cellular immune system. This phase 1 dose-escalating study was conducted to assess safety…”
Get full text

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates by Govindarajan, Dhanasekaran, Meschino, Steven, Guan, Liming, Clements, David E, ter Meulen, Jan H, Casimiro, Danilo R, Coller, Beth-Ann G, Bett, Andrew J

“…Highlights • Subunit DEN-80E protein was evaluated as monovalent and tetravalent formulations for immunogenicity and efficacy in non-human primates. •…”
Get full text

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells by Wee, Edmund G., Ondondo, Beatrice, Berglund, Peter, Archer, Jacob, McMichael, Andrew J., Baltimore, David, ter Meulen, Jan H., Hanke, Tomáš

“…To be effective against HIV type 1 (HIV-1), vaccine-induced T cells must selectively target epitopes, which are functionally conserved (present in the majority…”
Get full text

Abstract 5919: Component-specific qPCR assays for characterization and identity testing of multigenome ZVex®, a dendritic cell-targeting lentiviral vector platform by Bajaj, Anshika, Lin, Tsai-Yu, Ngo, Lisa Y., Murphy, Michele, Kelley-Clarke, Brenna, Gombotz, Wayne R., Meulen, Jan H. ter, Berglund, Peter

“…Background: ZVex is a novel, integration-deficient, dendritic cell-targeting lentiviral vector platform currently being evaluated in clinical trials in sarcoma…”
Get full text

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma by Halwani, Ahmad S., Panizo, Carlos, Isufi, Iris, Herrera, Alex F., Okada, Craig Y., Cull, Elizabeth H., Kis, Bela, Chaves, Jorge M., Bartlett, Nancy L., Ai, Weiyun, de la Cruz-Merino, Luis, Bryan, Locke J., Houot, Roch, Linton, Kim, Briones, Javier, Chau, Ian, von Keudell, Gottfried R., Lu, Hailing, Yakovich, Adam, Chen, Michael, Meulen JH, ter, Yurasov, Sergey, Hsu, Frank J., Flowers, Christopher R.

“…Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression…”
Get full text

Abstract 2506: Preclinical characterization of LV305, a lentiviral vector targeting tumors expressing NY-ESO-1 by Albershardt, Tina C., Campbell, David J., Parsons, Andrea J., ter Meulen, Jan H., Berglund, Peter

“…The cancer-testis antigen, NY-ESO-1, is an attractive tumor antigen target for cancer immunotherapy, because it is expressed in numerous cancer types (e.g.,…”
Get full text

Abstract 2505: Therapeutic efficacy of the ZVex™ and GLAAS™ platforms in a B16-F10/hCAIX melanoma mouse model by Campbell, David J., Reeves, Rebecca S., Flynn, Patrick A., Robbins, Scott H., Berglund, Peter, ter Meulen, Jan H.

“…ZVex™ and GLAAS™ are two dendritic-cell (DC) targeting platform technologies designed to enhance immune responses through the in vivo induction of antigen…”
Get full text

Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically by Seo, Yongwoo David, Zhou, Jing, Morse, Kevin, Patino, Jeremy, Mackay, Sean, Kim, Edward Y., Conrad, Ernest U., O'Malley, Ryan Blair, Cranmer, Lee D., Lu, Hailing, Hsu, Frank J., Xu, Yuexin, Loggers, Elizabeth Trice, Hain, Taylor, Pillarisetty, Venu Gopal, Kane, Gabrielle, Riddell, Stanley, ter Meulen, Jan H., Jones, Robin Lewis, Pollack, Seth

“…Abstract only 71 Background: Soft tissue sarcomas (STS) are heterogeneous tumors which are morbid and lethal. G100 is under investigation in multiple clinical…”
Get full text

Abstract 702: DCVex(TM): A novel integration-deficient lentivector technology that incorporates genetic and post-translational elements to target dendritic cells by Tareen, Semih U., Kelley-Clarke, Brenna, Nicolai, Christopher J., Slough, Megan M., Vin, Chintan D., Hoeven, Neal Van, Robbins, Scott H., Meulen, Jan H. ter, Berglund, Peter

“…With the goal of creating antigen-directed immunotherapeutics that can be safely administered directly to patients, Immune Design has developed a platform of…”
Get full text

Abstract 2817: DCVex(TM): A novel DC-targeted vector platform for cancer immunotherapy by Albershardt, Tina C., Tareen, Semih U., Odegard, Jared M., Campbell, David J., Flynn, Patrick, Robbins, Scott H., Berglund, Peter, Meulen, Jan H. ter

“…Dendritic cells (DCs) are essential for the initiation of T cell responses and are therefore an attractive target for cancer immunotherapy. The DC vaccine,…”
Get full text

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease: The Development of Dengue Vaccines by COLLER, Beth-Ann G, CLEMENTS, David E, BETT, Andrew J, SAGAR, Sangeetha L, TER MEULEN, Jan H

Get full text